Global Autism Spectrum Disorders Treatment Market Size

Autism Spectrum Disorders Treatment Market Analysis

The autism spectrum disorders treatment market is expected to register a CAGR of more than 7% over the forecast period, 2022-2027.

The COVID-19 pandemic has significantly impacted the autism disorders treatment market. This can be attributed to the fact that the pandemic caused supply chain disruptions in the pharmaceutical industry which led to problems in seeking treatment for autism spectrum disorders. Thus, the pandemic had a short-term negative impact on the market. In addition, as per a June 2021 published article titled, "Leveraging Technology for the Wellbeing of Individuals With Autism Spectrum Disorder and Their Families During Covid-19", one-way technology can be used during the pandemic for families with autism spectrum disorder (ASD) is through telehealth, which refers to providing various remote services electronically, such as patient care, education, and monitoring. Thus, telehealth has aided in meeting the rising demand for autism spectrum disorder treatment, thereby contributing to the market growth. Also, as per a December 2021 published study titled, "Coping with autism during lockdown period of the COVID-19 pandemic", the COVID-19 pandemic disrupted routines, triggered behavioral issues in individuals with ASD, and impacted the coping skills of both individuals and families, along with the mental health and well-being of the family. Such studies indicate the significantly high demand for autism spectrum disorders treatment amid the pandemic, thereby depicting an overall positive impact on the market.

The growth of the market can be attributed to the factors such as the increasing burden of autism spectrum disorder worldwide, rising awareness about the condition and available treatment options for autism spectrum disorder, as well as the growing number of investments in autism spectrum disorder.

For instance, as per a March 2022 update by the World Health Organization (WHO), about one in 100 children has autism. In addition, as per an October 2021 published study titled "Prevalence of Autism Spectrum Disorder and Co-morbidities in Children and Adolescents: A Systematic Literature Review," thirteen studies on the prevalence of autism spectrum disorder and 33 on the prevalence of co-morbidities were included. Prevalence of ASD was 1.70 and 1.85% in the United States in children aged 4 and 8 years, respectively, while the prevalence in Europe ranged between 0.38 and 1.55%. Additionally, current evidence is supportive of a global increase in autism spectrum disorder prevalence over the past years. However, the growing number of investments is also a major factor driving the market growth. For instance, in November 2021, Yamo Pharmaceuticals, LLC, reported that The Autism Impact Fund had made a capital investment in Yamo to support a Phase II study of L1-79 in adolescents and adults with an autism spectrum disorder. L1-79, the company's lead candidate, is a tyrosine hydroxylase inhibitor designed to modulate the catecholaminergic pathways implicated in autism spectrum disorder (ASD) and thus impact the socialization and communication symptoms in individuals with ASD.

However, the high cost of autism spectrum disorder treatment and diagnosis, as well as stringent regulations about product approval, are the major factors hindering the market growth.